Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 37 No. 2
PSYCHOPHARMACOLOGY BULLETIN

VOL 37 No. 2

Articles in This Issue

DRUG DISPOSITION & PHARMACOKINETICS

Alzheimer’s Disease and the Glutamate NMDA Receptor

Current treatment of Alzheimer’s disease (AD) has focused on the use of cholinesterase inhibitors. This review emphasizes emerging therapies for the treatment and/or prevention of AD, with a focus on glutamatergic excitotoxicity in dementia and...
DRUG DISPOSITION & PHARMACOKINETICS

What Is a Significant Response in Drug Studies of Attention- Deficit/Hyperactivity Disorder: Statistical Significance Is Necessary, But Is It Sufficient?

The methods used to report data from clinical treatment trials can influence the interpretation of the results. Reporting that a study drug achieves a statistically significant result does not provide the absolute likelihood or magnitude...
EVIDENCE-BASED MEDICINE

Evidence-Based Mental Health Use of Anticonvulsants During Pregnancy

There are many pertinent issues surrounding the treatment of bipolar disorder during pregnancy. Unfortunately, while there are numerous observational reports in the literature, there is limited information concerning the safety and efficacy of particular treatments...
EVIDENCE-BASED MEDICINE

Effect of Bupropion SR on Specific Symptom Clusters of Depression: Analysis of the 31-Item Hamilton Rating Scale for Depression

Principal component (PC) analysis is a statistical technique that has been used to identify core depression symptoms on the Hamilton Rating Scale for Depression (HAM-D). PC analysis is also a useful method to identify unidimensional...
TRANSLATIONAL NEUROSCIENCE

Incipient Neurovulnerability and Neuroprotection in Early Psychosis

The objective of this study was to review the implications of altered regulatory mechanisms of progenitor cell generation and death for neurodevelopment and adult brain functioning in early intervention in schizophrenia and related disorders. MEDLINE...
GENERAL PSYCHOPHARMACOLOGY

Can Serotonin and Fluoxetine Levels in Plasma and Platelets Predict Clinical Response in Depression?

We describe the clinical response and the area under the concentration-time curve (AUC) of fluoxetine and serotonin levels in plasma and platelets in 10 depressive patients treated with 20 mg/day of fluoxetine for 30 days....
GENERAL PSYCHOPHARMACOLOGY

5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

The 5-HT2A receptor promoter -1438G/A polymorphism, which is in complete linkage disequilibrium with the 5-HT2A 102T/C polymorphism, may be related to antipsychotic response. The aim of this paper is to determine relationships between the -1438G/A...
GENERAL PSYCHOPHARMACOLOGY

Therapeutic Implications of HPA Axis Abnormalities in Alzheimer’s Disease: Review and Update

The adaptive and maladaptive roles of the hypothalamic-pituitary-adrenal (HPA) axis in stressful conditions and in disorders such as major depression, posttraumatic stress disorder, and Cushing’s syndrome have been the subject of substantial ongoing study. In...